10-Q: Scientist Home Future Health Reports Q2 2026 Results, Faces Going Concern

Scientist Home Future Health Limited reported increased revenues for the six months ended June 30, 2026, but also significant net losses and a substantial decrease in cash, raising going concern doubts.

Summary

• Scientist Home Future Health Limited reported revenues of $84,303 for the three months ended June 30, 2026, and $273,059 for the six months ended June 30, 2026, primarily from retail sales of health supplements and topical creams, and physical check-up services.
• The company incurred a net loss of $97,852 for the three months ended June 30, 2026, and $199,924 for the six months ended June 30, 2026.
• Cash and cash equivalents decreased significantly from $68,888 as of December 31, 2025, to $9,047 as of June 30, 2026.
• The company faces substantial doubt regarding its ability to continue as a going concern due to net losses and net current liabilities.
• General and administrative expenses increased significantly in the current period compared to the prior year.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as a negative sentiment due to significant net losses, a substantial decrease in cash, and a going concern warning, despite revenue growth.

Positives

• Revenue increased to $84,303 for the three months ended June 30, 2026, and $273,059 for the six months ended June 30, 2026, up from $31,552 and $76,376 respectively in the prior year.
• The company's mission focuses on developing sustainable rehabilitation solutions for degenerative diseases.
• The company has a presence in Hong Kong and serves a diverse customer base valuing health and wellness.

Negatives

• The company incurred a net loss of $97,852 for the three months ended June 30, 2026, and $199,924 for the six months ended June 30, 2026, compared to losses of $37,213 and $31,154 in the prior year.
• Cash and cash equivalents decreased by approximately 87% from $68,888 to $9,047 between December 31, 2025, and June 30, 2026.
• Net current liabilities were $214,975 as of June 30, 2026.
• The company's independent auditors have expressed substantial doubt about its ability to continue as a going concern.
• General and administrative expenses increased substantially to $126,961 for the three months and $288,101 for the six months ended June 30, 2026, from $51,687 and $64,382 in the prior year.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern within one year of the financial statement issuance date due to net losses and net current liabilities.
• The company's ability to continue as a going concern is dependent on improving profitability and continuing financial support from major shareholders.
• Future financing, if needed, may not be available or may be on unsatisfactory terms, potentially including undue restrictions or substantial dilution.
• The company has a single vendor accounting for 100% of its cost of revenues, creating significant vendor concentration risk.
• The company lacks sufficient segregation of duties, an independent board of directors, and an audit committee, and does not have written documentation of internal control policies and procedures, indicating material weaknesses in internal controls.

Future Outlook

The company's ability to continue as a going concern is dependent on improving profitability and securing continuing financial support from its major shareholders. Management believes existing shareholders or external financing will provide necessary cash, but there is no assurance of availability or satisfactory terms.

Management Comments

• Management believes the existing shareholders or external financing will provide additional cash to meet the Companys obligations as they become due.
• Despite the amount of funds that the Company has raised in the past, no assurance can be given that any future financing, if needed, will be available or, if available, that it will be on terms that are satisfactory to the Company.
• Even if the Company can obtain additional financing, if needed, it may contain undue restrictions on its operations, in the case of debt financing, or cause substantial dilution for its shareholders, in the case of equity financing.

Industry Context

StockSavvy.ai notes that the health supplement and topical cream market, along with physical check-up services, is generally growing. However, Scientist Home Future Health Limited's significant losses and going concern issues suggest operational or financial challenges that are not typical for a healthy company in this sector, regardless of market trends.

Comparison to Industry Standards

• Companies in the health and wellness sector typically aim for profitability and positive cash flow. Scientist Home Future Health Limited's net loss of $199,924 for six months and negative equity of $86,324 are significantly worse than industry standards.
• A healthy cash position is crucial. Scientist Home Future Health Limited's cash balance of $9,047 is critically low compared to industry benchmarks, which often require substantial working capital for inventory, marketing, and operations.
• The significant increase in general and administrative expenses relative to revenue growth is a concern. Industry peers often demonstrate better cost control or a clearer path to revenue scaling that covers these expenses.
• The reliance on a single vendor for 100% of cost of revenues is a substantial deviation from industry best practices, which emphasize diversified supply chains to mitigate risk.

Corporate Governance

Legal Proceedings

• The company's officers and directors are not aware of any threatened or pending litigation that would have a material adverse effect on the company.

Related Party Transactions

• The company rents office spaces from Related party A, an entity owned by the CEO.
• The company purchases trading goods and courier services from Related party B, an entity owned by the CEO.
• Vendor A, which supplies 100% of the company's cost of revenues, is owned by the CEO.
• Amounts due to Related party B (operating) were $165,364 as of June 30, 2026.
• A director advanced $27,790 to the company for working capital purposes.

Stakeholder Impact

• Shareholders face potential dilution if future equity financing is pursued.
• Shareholders are exposed to significant risk due to the company's going concern issues and substantial net losses.
• Creditors and suppliers may face uncertainty regarding timely payment due to the company's liquidity challenges.
• Employees may experience uncertainty regarding job security due to the company's financial instability.

Next Steps

• Management plans to rectify material weaknesses in internal controls by implementing an independent board of directors, establishing written policies and procedures, and hiring additional accounting personnel upon completion of a reverse merger or similar business acquisition.
• The company will continue to focus on its mission to develop sustainable rehabilitation solutions for degenerative diseases.
• Management is seeking financial support from existing shareholders or external financing to meet obligations.

Key Dates

Recommendation

The company exhibits severe financial distress, including significant net losses, a drastic reduction in cash reserves, negative equity, and a formal going concern warning from its auditors. The material weaknesses in internal controls and heavy reliance on related parties for operations and supplies further exacerbate these risks. Despite revenue growth, the financial performance is deteriorating rapidly, making it a high-risk investment.

Keywords

health supplements, topical creams, physical check-up services, retail trading, going concern, net loss, cash flow, financial statements